公开(公告)号：US10259867B2

公开(公告)日：2019-04-16

申请号：US15583487

申请日：2017-05-01

Applicant: Janssen Biotech, Inc.

Inventor： Jill Giles-Komar ,  David M. Knight ,  David Peritt ,  Bernard Scallon ,  David Shealy

IPC: A61K39/395 ,  C07K16/24 ,  A61K45/06 ,  A61K39/00

Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.

公开(公告)号：US20180079809A1

公开(公告)日：2018-03-22

申请号：US15830586

申请日：2017-12-04

Applicant: Janssen Biotech, Inc.

Inventor： Jill Giles-Komar ,  George Heavner ,  David Knight ,  Jinquan Luo ,  David Peritt ,  Bernard Scallon ,  David Shealy

IPC: C07K16/24 ,  C12Q1/68 ,  C07K14/54 ,  A61K31/56 ,  A61K38/27 ,  A61K39/395 ,  A61K45/06 ,  A61K51/00 ,  A61K31/137 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K31/137 ,  A61K31/56 ,  A61K38/27 ,  A61K39/3955 ,  A61K45/06 ,  A61K51/00 ,  A61K2039/505 ,  C07K14/54 ,  C07K14/5434 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C12Q1/6876

Abstract: An anti-IL-12 antibody or fragment thereof that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

公开(公告)号：US20160319014A1

公开(公告)日：2016-11-03

申请号：US15217099

申请日：2016-07-22

Applicant: Janssen Biotech, Inc.

Inventor： Jill Giles-Komar ,  George Heavner ,  David Knight ,  Jinquan Luo ,  David Peritt ,  Bernard Scallon ,  David Shealy

IPC: C07K16/24 ,  C12Q1/68

CPC classification number: C07K16/244 ,  A61K31/137 ,  A61K31/56 ,  A61K38/27 ,  A61K39/3955 ,  A61K45/06 ,  A61K51/00 ,  A61K2039/505 ,  C07K14/54 ,  C07K14/5434 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C12Q1/6876

Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract translation: 结合IL-12蛋白的一部分对应于至少一个氨基酸残基的抗IL-12抗体，其选自残基15,17-21,23,40-43,45-47,54 -56和58-62的IL-12的p40亚基的氨基酸序列，包括编码至少一种抗IL-12抗体，载体，宿主细胞，转基因动物或植物的分离的核酸，以及制备方法 并且其使用在诊断和/或治疗组合物，方法和装置中具有应用。

公开(公告)号：US09428579B2

公开(公告)日：2016-08-30

申请号：US14512757

申请日：2014-10-13

Applicant: Janssen Biotech, Inc.

Inventor： Jill Giles-Komar ,  George Heavner ,  David Knight ,  Jinquan Luo ,  David Peritt ,  Bernard Scallon ,  David Shealy

IPC: A61K39/395 ,  C07K16/24 ,  C07K14/54 ,  A61K31/137 ,  A61K31/56 ,  A61K38/27 ,  A61K45/06 ,  A61K51/00 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K31/137 ,  A61K31/56 ,  A61K38/27 ,  A61K39/3955 ,  A61K45/06 ,  A61K51/00 ,  A61K2039/505 ,  C07K14/54 ,  C07K14/5434 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C12Q1/6876

Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract translation: 结合IL-12蛋白的一部分对应于至少一个氨基酸残基的抗IL-12抗体，其选自残基15,17-21,23,40-43,45-47,54 -56和58-62的IL-12的p40亚基的氨基酸序列，包括编码至少一种抗IL-12抗体，载体，宿主细胞，转基因动物或植物的分离的核酸，以及制备方法 并且其使用在诊断和/或治疗组合物，方法和装置中具有应用。

公开(公告)号：US09321836B2

公开(公告)日：2016-04-26

申请号：US14068010

申请日：2014-02-18

Applicant: JANSSEN BIOTECH, INC.

Inventor： George Heavner ,  David M. Knight ,  Jill Giles-Komar ,  Bernard Scallon ,  David Shealy

IPC: A61K39/395 ,  A61K38/18 ,  A61K38/19 ,  A61K38/27 ,  A61K45/06 ,  C07K16/24 ,  G01N33/53 ,  C07K16/42 ,  G01N33/566 ,  A61K39/00

CPC classification number: C07K16/241 ,  A61K9/19 ,  A61K38/1816 ,  A61K38/19 ,  A61K38/27 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/42 ,  C07K16/4241 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/566 ,  Y02A50/386 ,  Y02A50/412 ,  Y10S514/825 ,  Y10S514/826

Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.

Abstract translation: 本发明涉及包含SEQ ID NO：1,2和3的所有重链可变CDR区和/或SEQ ID NO：4,5和6的所有轻链可变CDR区的抗TNF抗体， 特异于至少一种人肿瘤坏死因子α（TNF）蛋白或其片段，以及编码这种抗TNF抗体的核酸，互补核酸，载体，宿主细胞，生产方法和治疗方法。

公开(公告)号：US20150291946A1

公开(公告)日：2015-10-15

申请号：US14618185

申请日：2015-02-10

Applicant: Janssen Biotech, Inc.

Inventor： Michael Naso ,  T. Shantha Raju ,  Bernard Scallon

IPC: C12N9/24 ,  C12N15/85

CPC classification number: C12N9/2402 ,  C07K16/00 ,  C07K16/241 ,  C07K2317/41 ,  C07K2317/72 ,  C07K2317/732 ,  C12N15/85 ,  C12P21/005 ,  C12Y302/01018

Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.

Abstract translation: 通过用编码唾液酸酶的载体序列转染表达含Fc的蛋白质的细胞系，通过改变Fc区中寡糖的唾液酸化来控制含Fc的蛋白质，例如抗体的性质。 经修饰的含Fc蛋白质具有治疗效用，其中希望控制对FcγRI，FcγRIIA和FcγRIIIA受体的一种或多种的亲和力，ADCC活性，巨噬细胞或单核细胞活化，血清半衰期和 亲和力

公开(公告)号：US08980626B2

公开(公告)日：2015-03-17

申请号：US14163469

申请日：2014-01-24

Applicant: Janssen Biotech, Inc.

Inventor： Jill Carton ,  Jin Lu ,  Bernard Scallon ,  Linda Snyder

IPC: C12N15/79 ,  C12P21/08 ,  C07K16/00 ,  C12N15/85

CPC classification number: C07K16/00 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2319/036 ,  C12N15/85 ,  C12N2800/22

Abstract: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.

公开(公告)号：US08894990B2

公开(公告)日：2014-11-25

申请号：US13669894

申请日：2012-11-06

Applicant: Janssen Biotech, Inc.

Inventor： Jill Giles-Komar ,  George Heavner ,  David Knight ,  Jinquan Luo ,  David Peritt ,  Bernard Scallon ,  David Shealy

IPC: A61K39/395 ,  C07K16/24 ,  A61K31/56 ,  A61K51/00 ,  A61K31/137 ,  C07K14/54 ,  A61K38/27 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K31/137 ,  A61K31/56 ,  A61K38/27 ,  A61K39/3955 ,  A61K45/06 ,  A61K51/00 ,  A61K2039/505 ,  C07K14/54 ,  C07K14/5434 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C12Q1/6876

Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriatic arthritis.

Abstract translation: 结合IL-12蛋白的一部分对应于至少一个氨基酸残基的抗IL-12抗体，其选自残基15,17-21,23,40-43,45-47,54 -56和58-62的IL-12的p40亚基的氨基酸序列，包括编码至少一种抗IL-12抗体，载体，宿主细胞，转基因动物或植物的分离的核酸，以及制备方法 并且其应用具有治疗IL-12相关疾病如牛皮癣关节炎的应用。

公开(公告)号：US20140141506A1

公开(公告)日：2014-05-22

申请号：US14163469

申请日：2014-01-24

Applicant: Janssen Biotech, Inc.

Inventor： Jill Carton ,  Jin Lu ,  Bernard Scallon ,  Linda Snyder

IPC: C07K16/00

CPC classification number: C07K16/00 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2319/036 ,  C12N15/85 ,  C12N2800/22

Abstract: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.

Abstract translation: 抗体表达载体和质粒可以掺入用于转录抗体DNA的各种抗体基因部分和抗体在合适的宿主细胞中的表达。 表达载体和质粒具有有利于将抗体编码DNA连接到载体中的限制酶位点。 载体包含增强子和启动子序列，其可以变化以与宿主细胞中的转录因子相互作用，从而控制抗体编码DNA的转录。 试剂盒可以并入这些载体和质粒。